[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with symptoms highly suggestive of severe preeclampsia: severe occipital headache, visual scotomata, right upper quadrant pain, and significantly elevated blood pressure (168/108 mmHg). Her laboratory findings of thrombocytopenia (platelets 86,000/µL) and elevated liver enzymes (AST 145 U/L, ALT 162 U/L) further support this diagnosis. The urine protein/creatinine ratio of 0.5 is consistent with proteinuria, though not meeting the criteria for severe preeclampsia based on this alone (typically >0.3 with other signs of severe disease, or >5.0 for diagnostic criteria). The 3+ reflexes and clonus indicate hyperreflexia, another sign of central nervous system involvement in preeclampsia.\n\nGiven the severity of her symptoms and signs, immediate management is crucial.\n\nOption A: Administering IV labetalol is appropriate for blood pressure control, but planning for induction at 34 weeks is not the most immediate priority. While delivery is indicated, the timing needs to be more urgent given the severity.\n\nOption B: Initiating magnesium sulfate is essential for seizure prophylaxis in severe preeclampsia. However, proceeding with immediate induction of labor without considering fetal lung maturity might not be the absolute best next step if there's a possibility of delaying delivery slightly to administer corticosteroids.\n\nOption C: Initiating magnesium sulfate is critical for seizure prophylaxis. Administering betamethasone is indicated to promote fetal lung maturity, especially if delivery is anticipated soon. Given the severe features of preeclampsia, delivery within 24 hours is generally recommended to prevent further maternal and fetal complications. This option addresses both maternal safety (magnesium sulfate) and fetal well-being (betamethasone) while planning for timely delivery.\n\nOption D: Administering additional IV hydralazine and observing is insufficient given the persistent severe hypertension and the presence of other severe preeclampsia symptoms. Deferring delivery until 34 weeks is too long a delay in the face of severe disease.\n\nOption E: Starting oral labetalol and discharging the patient with outpatient follow-up is inappropriate and dangerous. Her condition is severe and requires inpatient management and likely delivery.\n\nConsidering the severity of the preeclampsia, the most appropriate next step is to initiate magnesium sulfate for seizure prophylaxis, administer betamethasone to promote fetal lung maturity, and plan for delivery within 24 hours.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with severe heart failure symptoms (NYHA class III), low ejection fraction (LVEF 20%), elevated filling pressures (RAP 18 mmHg, PCWP 32 mmHg), low cardiac index (CI 1.7 L/min/m²), and worsening renal function despite optimal medical therapy and CRT-D. He is INTERMACS profile 4, indicating a patient with advanced heart failure who is deteriorating.\n\nLet's analyze the options:\n\nA. Adding continuous IV milrinone as palliative inotropic therapy without advanced therapies: While milrinone can provide temporary symptomatic relief, it does not address the underlying mechanical issue or the need for advanced therapy in a patient with such severe, refractory heart failure. Given his INTERMACS profile and hemodynamic instability, palliative care alone is not the best definitive next step.\n\nB. Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge: Cardiac transplantation is a definitive therapy, but listing status 2 implies a less urgent need than his current clinical presentation suggests. Furthermore, patients with INTERMACS profile 4 and severe hemodynamic compromise often require mechanical support as a bridge to transplant to improve their condition and candidacy.\n\nC. Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR: Severe functional mitral regurgitation (MR) is present and contributing to his symptoms and elevated filling pressures. TEER can be a valuable intervention for functional MR in heart failure patients. However, given his profound hemodynamic instability (CI 1.6 L/min/m² after diuresis) and INTERMACS profile 4, addressing the overall pump dysfunction and potential for further deterioration might be more immediately critical than solely focusing on MR, although MR is a significant contributor.\n\nD. Refer for durable LVAD implantation as bridge to transplant or destination therapy: This patient has severe, refractory heart failure with low cardiac output and elevated filling pressures, making him a candidate for advanced heart failure therapies. An LVAD provides mechanical support, improves hemodynamics, reduces end-organ dysfunction, and can serve as a bridge to transplant or as destination therapy for patients not eligible for transplant. His INTERMACS profile 4 strongly suggests the need for mechanical circulatory support.\n\nE. Implant a percutaneous Impella device as bridge to decision in the ICU: An Impella is a temporary mechanical support device. While it can be used as a bridge to decision, his INTERMACS profile 4 and the need for a definitive solution suggest that a more durable therapy like an LVAD is likely indicated rather than a temporary device for decision-making, especially if he is a candidate for transplant or destination therapy.\n\nConsidering the patient's INTERMACS profile 4, severe symptoms, low cardiac output, and elevated filling pressures despite optimal medical therapy, a durable mechanical circulatory support device like an LVAD is the most appropriate next step to stabilize his condition, improve his hemodynamics, and provide a bridge to transplant or destination therapy. While TEER is a consideration for his MR, the overall severity of his heart failure and hemodynamic compromise makes LVAD implantation a more pressing and definitive intervention.\n\nThe answer is (D)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with classic signs and symptoms of Kawasaki disease: fever, conjunctival injection, cracked lips, rash, extremity changes, and cervical lymphadenopathy. The echocardiogram findings of diffuse coronary artery ectasia and mild LV dysfunction are also consistent with this diagnosis. The elevated inflammatory markers (CRP, ESR) and sterile pyuria further support the diagnosis.\n\nThe timing of treatment is crucial in Kawasaki disease. While the patient is beyond the typical 7-10 day window for initial IVIG treatment to prevent coronary artery abnormalities, the presence of coronary artery ectasia and LV dysfunction indicates ongoing inflammation and risk of further complications. Current guidelines suggest that even with coronary artery abnormalities present, IVIG is still indicated to reduce further progression and risk of aneurysm formation.\n\nLet's analyze the options:\n\nA. Single dose IVIG 2 g/kg plus high-dose aspirin only: This is a standard initial treatment for Kawasaki disease. Given the coronary artery ectasia, IVIG is still indicated. High-dose aspirin is used for its anti-inflammatory and antiplatelet effects.\n\nB. IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg: Corticosteroids are generally reserved for patients who are refractory to IVIG or have very high-risk features. While this patient has coronary ectasia, it's not explicitly stated as \"high-risk\" in a way that would immediately warrant steroids in addition to IVIG.\n\nC. IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg: Infliximab is a biologic agent used for refractory Kawasaki disease or when there are concerns about IVIG resistance. Low-dose aspirin is typically used for secondary prevention of thrombosis after coronary artery abnormalities have resolved or stabilized. High-dose aspirin is used during the acute phase.\n\nD. IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day: Anakinra is an IL-1 receptor antagonist that can be used in specific inflammatory conditions, but it is not a standard first-line treatment for Kawasaki disease, especially not in conjunction with IVIG and aspirin in this scenario.\n\nE. High-dose aspirin alone because presentation is after day 10 of illness: While the optimal window for IVIG to prevent coronary artery abnormalities is before day 10, the presence of established coronary artery ectasia and LV dysfunction means that further inflammation needs to be addressed. IVIG is still beneficial in reducing the risk of further dilatation or aneurysm formation even after day 10. Aspirin alone would not be sufficient to address the underlying inflammatory process driving the coronary artery changes.\n\nConsidering the patient has established coronary artery ectasia and LV dysfunction, IVIG is still indicated to reduce further progression. High-dose aspirin is appropriate for the acute phase. Therefore, option A represents the most appropriate initial treatment strategy.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms and findings consistent with pulmonary arterial hypertension (PAH), specifically connective tissue disease-associated PAH (CTD-PAH) given her mixed connective tissue disease and positive anti-U1-RNP. Her hemodynamics (mPAP 46 mmHg, PAOP 9 mmHg, PVR 9 Wood units) confirm precapillary pulmonary hypertension. The reduced RV function and elevated PASP on TTE further support this. She desires pregnancy, which is a contraindication for many PAH therapies, particularly endothelin receptor antagonists (ERAs) and prostacyclins due to teratogenicity.\n\nLet's analyze the options:\n\nA. Amlodipine after acute vasoreactivity testing: Vasoreactivity testing is typically performed in idiopathic PAH, and even then, only a small percentage of patients respond well to calcium channel blockers. CTD-PAH patients are less likely to be vasoreactive. Furthermore, amlodipine is generally not the first-line therapy for her hemodynamic profile and functional class.\n\nB. Initiate dual oral therapy with ambrisentan and tadalafil: This is a standard initial approach for intermediate-risk PAH patients according to current guidelines. Ambrisentan is an ERA, and tadalafil is a PDE-5 inhibitor. While ERAs have teratogenic potential, the risk needs to be weighed against the severity of her PAH and the desire for pregnancy. However, given the desire for pregnancy, this option needs careful consideration regarding the teratogenic risks of ambrisentan.\n\nC. Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor: This is typically reserved for high-risk PAH patients. Her hemodynamics and functional status, while significant, do not immediately place her in the highest risk category requiring upfront triple therapy, especially considering the complexity and risks of IV prostacyclins, particularly in the context of pregnancy planning.\n\nD. Start inhaled treprostinil monotherapy and observe functional response: Inhaled prostacyclins can be used, but monotherapy might not be sufficient for her hemodynamic severity. Furthermore, the teratogenic potential of prostacyclins remains a concern for pregnancy.\n\nE. Use riociguat monotherapy given connective tissue disease-associated PAH: Riociguat is a stimulator of soluble guanylate cyclase (sGC) and is approved for PAH, including CTD-PAH. It is a reasonable option for initial therapy, especially in patients with CTD-PAH. Importantly, riociguat is contraindicated in pregnancy due to teratogenicity, but it is a viable option for initial management before pregnancy is attempted, and the patient can be counseled on its risks and the need for effective contraception. Given the options, and considering the desire for pregnancy, a therapy that can be initiated and then potentially adjusted or switched closer to conception, or a therapy that is considered a good initial choice for CTD-PAH, is preferred. Dual oral therapy (B) is a strong contender, but the teratogenic risk of ERAs is significant. Riociguat (E) is also a good option for CTD-PAH and can be initiated. However, the question asks for the *most appropriate initial advanced therapy strategy*. Current guidelines often recommend dual oral therapy for intermediate-risk PAH. The teratogenic risk of ERAs is a major consideration for pregnancy, but it doesn't preclude its use as an initial therapy if the patient is counseled and uses effective contraception.\n\nRe-evaluating the options in light of pregnancy desire:\nThe desire for pregnancy is a critical factor. Both ERAs (ambrisentan) and prostacyclins (epoprostenol, treprostinil) are teratogenic. Riociguat is also teratogenic. This means that any of these advanced therapies will require significant counseling regarding contraception and potential risks if pregnancy occurs.\n\nConsidering the hemodynamic severity (mPAP 46 mmHg), dual oral therapy (ambrisentan + tadalafil) is a standard and effective initial approach for intermediate-risk PAH. While teratogenic, it is a well-established treatment. The patient would need to be on highly effective contraception.\n\nRiociguat is also a good option for CTD-PAH. However, the question asks for the *most appropriate initial advanced therapy strategy*. Dual oral therapy is often considered the standard of care for intermediate-risk PAH.\n\nLet's consider the specific wording: \"most appropriate initial advanced therapy strategy\".\nOption B, dual oral therapy, is a widely accepted initial strategy for intermediate-risk PAH. The teratogenic risk is a significant counseling point, but it doesn't make it inappropriate as an initial therapy if managed with contraception.\n\nOption E, riociguat monotherapy, is also a reasonable choice for CTD-PAH. However, dual therapy is often preferred for better efficacy in intermediate-risk patients.\n\nGiven the options and the current understanding of PAH management, dual oral therapy with an ERA and a PDE-5 inhibitor is a strong initial strategy for intermediate-risk PAH, even with the desire for pregnancy, provided appropriate counseling and contraception are implemented.\n\nFinal consideration: The question asks for the *most appropriate initial advanced therapy strategy*. Dual oral therapy is a cornerstone of initial management for intermediate-risk PAH. While pregnancy is a concern, it doesn't preclude initiating effective therapy with proper counseling.\n\nThe answer is B"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient presents with severe symptoms of hyperemesis gravidarum, including significant weight loss, dehydration (orthostatic tachycardia, low sodium and potassium), and metabolic derangements (ketonuria, low bicarbonate). She has failed initial outpatient management with pyridoxine/doxylamine and rectal promethazine. Her symptoms are severe enough to warrant hospitalization for IV fluids, electrolyte repletion, and further management.\n\nLet's analyze the options:\n\nA. Starting oral ondansetron and discharging her with outpatient follow-up might be considered if her symptoms were less severe or if she had responded to initial oral medications. However, her current condition suggests she needs more aggressive management and monitoring.\n\nB. A continuous subcutaneous metoclopramide infusion is a reasonable outpatient option for some patients, but given the severity of her symptoms and failure of prior oral/rectal medications, hospitalization is likely necessary for initial stabilization and to ensure adequate hydration and nutrition.\n\nC. Administering IV ondansetron is appropriate for severe nausea and vomiting. However, the statement \"admit for parenteral nutrition via PICC line\" implies that she is already being admitted. If she is being admitted, then parenteral nutrition might be considered if she cannot tolerate oral or enteral intake for an extended period. However, the question asks for the *next-step pharmacologic management in addition to IV fluids and electrolyte repletion*. While admission is likely, the immediate pharmacologic step in conjunction with fluids and electrolytes is key.\n\nD. Transdermal scopolamine can be used for nausea and vomiting, but it's not typically the first-line agent for hyperemesis gravidarum, especially in severe cases. Mirtazapine is an antidepressant with antiemetic properties, but its use in hyperemesis gravidarum is less established and it's not the most appropriate immediate pharmacologic intervention.\n\nE. Administering IV chlorpromazine is a reasonable option for severe nausea and vomiting in pregnancy, and it can be effective when other agents have failed. Transitioning to scheduled IV ondansetron or metoclopramide in the hospital is also a sensible plan for ongoing management. Given her severe symptoms and failure of initial treatments, inpatient management with IV medications is indicated. Chlorpromazine is a potent antiemetic that can be used in this setting.\n\nConsidering the severity of her symptoms and failure of initial outpatient management, hospitalization is necessary. Within the hospital, IV medications are the next step. Option E suggests IV chlorpromazine, which is a valid choice for severe hyperemesis, and a plan for further IV antiemetics. While IV ondansetron (as in option C) is also a good choice, option E provides a more comprehensive immediate pharmacologic step and a plan for ongoing management within the hospital setting. The question asks for the *most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion*. This implies an immediate intervention.\n\nLet's re-evaluate option C. If she is being admitted, then IV ondansetron is a strong contender. However, the phrasing \"admit for parenteral nutrition via PICC line\" might be premature without assessing her response to IV fluids and antiemetics first.\n\nComparing E and C, both involve IV medications and hospitalization. Option E starts with IV chlorpromazine and then plans for other IV antiemetics. Option C starts with IV ondansetron and then mentions admission for parenteral nutrition. The question asks for the *next-step pharmacologic management*.\n\nGiven the severity and failure of prior treatments, a potent IV antiemetic is needed. Both ondansetron and chlorpromazine are options. However, the prompt asks for the *most appropriate next-step pharmacologic management*. If hospitalization is implied by the need for IV fluids and electrolyte repletion, then starting an effective IV antiemetic is the immediate pharmacologic step. Option E provides a specific IV medication (chlorpromazine) and a plan for further management.\n\nLet's consider the teratogenic risk mentioned. Ondansetron has some concerns regarding cardiac malformations in early pregnancy, although the absolute risk is low. Chlorpromazine is generally considered safe in pregnancy for severe nausea and vomiting.\n\nGiven the patient's severe symptoms and failure of initial treatments, hospitalization is clearly indicated. The question asks for the *next-step pharmacologic management in addition to IV fluids and electrolyte repletion*. This means we are looking for an immediate medication to administer.\n\nOption E: Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital. This is a strong option because chlorpromazine is effective for severe nausea and vomiting, and it addresses the immediate need for pharmacologic intervention in the hospital.\n\nOption C: Administer IV ondansetron and admit for parenteral nutrition via PICC line. While IV ondansetron is appropriate, the immediate need for parenteral nutrition might not be established yet.\n\nConsidering the options, option E provides a concrete immediate pharmacologic step with a plan for ongoing management, which is crucial for a patient with severe hyperemesis gravidarum who has failed initial treatments.\n\nThe final answer is $\\boxed{E}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a constellation of symptoms highly suggestive of diffuse alveolar hemorrhage (DAH) and acute kidney injury (AKI) with glomerulonephritis. The rapid onset of hypoxemia, hemoptysis, and renal involvement after a severe sepsis episode is concerning.\n\nLet's analyze the options:\n\nA. High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis: While vasculitis is a possibility, the ANCA panel is negative. However, some ANCA-negative vasculitides exist. The presentation is consistent with a systemic inflammatory process affecting the lungs and kidneys.\n\nB. Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology: Anti-GBM disease typically presents with DAH and rapidly progressive glomerulonephritis. However, serology for anti-GBM antibodies is usually positive. While false negatives can occur, it's less likely to be the primary suspicion without any positive serology.\n\nC. Supportive care only, assuming septic coagulopathy-related lung injury: The patient's coagulation parameters (platelets, PT/INR, PTT, fibrinogen) are normal, making a primary coagulopathy-induced lung injury less likely as the sole cause of DAH and glomerulonephritis. While supportive care is crucial, it may not address the underlying inflammatory process.\n\nD. Kidney biopsy as soon as feasible to guide immunosuppression decisions: A kidney biopsy is an excellent diagnostic tool to characterize the type of glomerulonephritis and guide treatment. Given the renal involvement and the need to differentiate between various causes of glomerulonephritis, a biopsy would provide definitive histological information. This is particularly important in guiding immunosuppressive therapy.\n\nE. Start rituximab and prednisone for suspected immune-complex GN related to sepsis: Immune-complex glomerulonephritis can occur post-infection. Rituximab and prednisone are used for immune-complex GN. However, without histological confirmation, initiating this treatment empirically might not be the most appropriate first step, especially when a biopsy can provide more specific diagnostic information.\n\nConsidering the rapid progression of DAH and AKI with glomerulonephritis, and the need to differentiate between various causes, a kidney biopsy is the most appropriate next step to obtain a definitive diagnosis and guide subsequent management, including the decision for immunosuppression. While vasculitis is a strong consideration, the negative ANCA panel and the need for histological confirmation of the renal pathology make the biopsy paramount.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with signs and symptoms of severe heart failure in a 6-week-old infant, including poor feeding, tachypnea, sweating with feeds, failure to thrive, hepatomegaly, gallop rhythm, and a holosystolic murmur. The echocardiogram reveals a dilated left ventricle with a severely reduced ejection fraction (EF 20%), moderate mitral regurgitation, and normal right ventricular function. The CXR shows cardiomegaly and pulmonary overcirculation, consistent with heart failure. The patient has stabilized with milrinone and diuretics, indicating a need for ongoing management of severe heart failure.\n\nLet's analyze the options:\n\nA. Discontinuing inotropes as soon as EF improves above 35% and transitioning to oral therapy is premature. The EF of 20% is critically low, and while improvement is good, it doesn't negate the need for a long-term strategy. Oral therapy alone may not be sufficient for such severe dysfunction.\n\nB. Urgently listing for heart transplant as status 1A is a strong consideration given the severity of dilated cardiomyopathy and high mortality in infants. However, it's important to consider other potential interventions or bridges to transplant.\n\nC. Beginning high-dose IVIG for presumed viral myocarditis is a treatment for a specific etiology. While viral myocarditis is a possibility, the diagnosis is not confirmed, and even with treatment, severe LV dysfunction may persist. Deferring mechanical support might be too passive given the critical state.\n\nD. Evaluating for durable LVAD candidacy as a bridge to transplant or recovery is a crucial step in managing severe pediatric heart failure. LVADs can provide hemodynamic support, improve organ perfusion, and allow for recovery or serve as a bridge to transplantation. Given the dilated cardiomyopathy and severe LV dysfunction, this is a highly appropriate next step to consider.\n\nE. Scheduling elective mitral valve repair is not the most appropriate next step. While moderate mitral regurgitation is present, it is likely secondary to LV dilation and dysfunction. Addressing the underlying cardiomyopathy is the priority, and mitral valve repair might be considered later if it remains a significant issue after addressing the primary problem or as part of a transplant strategy.\n\nConsidering the severe dilated cardiomyopathy and the patient's young age, a heart transplant is a likely long-term goal. However, before definitively listing for transplant, evaluating for mechanical support like an LVAD is a standard and appropriate step. An LVAD can stabilize the patient, improve their condition, and potentially allow for recovery or serve as a bridge to transplant. Therefore, evaluating for LVAD candidacy is the most appropriate next step in definitive management planning.\n\nThe answer is (D)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with symptoms and laboratory findings highly suggestive of superimposed preeclampsia with severe features in the setting of SLE. Key indicators include severe headache, visual blurring, elevated blood pressure (164/102 mmHg), increasing edema, elevated creatinine, elevated urine protein/creatinine ratio, and evidence of hemolysis (though platelets are not critically low, the constellation of symptoms points towards this). The presence of RBC casts in the urinalysis further supports a renal insult, which can be seen in both preeclampsia and lupus nephritis flares. However, the rapid onset of severe symptoms, particularly the headache and visual changes, in conjunction with the elevated blood pressure, strongly favors preeclampsia.\n\nLet's analyze the options:\n\nA. Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery: This is the most appropriate management. Preeclampsia with severe features, especially with neurological symptoms like severe headache and visual disturbances, warrants immediate delivery to prevent maternal and fetal complications. The gestational age of 36+1 weeks makes delivery a reasonable option.\n\nB. Increase azathioprine dose and schedule induction at 39 weeks if no further worsening: Azathioprine is an immunosuppressant and not directly indicated for acute preeclampsia. Delaying delivery until 39 weeks is too long given the severe features of preeclampsia.\n\nC. Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring: While a lupus nephritis flare is possible given the low complement and increased anti-dsDNA, the acute onset of severe headache and visual changes, along with the significantly elevated blood pressure, points more strongly to preeclampsia. Treating a lupus flare with steroids might not adequately address the immediate threat of preeclampsia.\n\nD. Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks: Magnesium sulfate is indicated for seizure prophylaxis in preeclampsia with severe features. Blood pressure control is also crucial. However, delaying delivery until 37 weeks might be too long if the patient's condition deteriorates. Immediate delivery is often preferred for severe preeclampsia at this gestational age.\n\nE. Add IV cyclophosphamide for nephritis flare and plan delivery after disease control: Cyclophosphamide is a potent immunosuppressant used for severe lupus nephritis flares. However, similar to option C, the primary concern here is superimposed preeclampsia with severe features, which requires immediate intervention. Delaying delivery until disease control might be too risky.\n\nConsidering the severe features of preeclampsia (severe headache, visual blurring, severe hypertension) at 36+1 weeks gestation, immediate delivery is the safest course of action for both mother and fetus.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has severe ARDS (PaO2/FiO2 ratio of 70) refractory to lung-protective ventilation, paralysis, and prone positioning. She is on vasopressors, indicating hemodynamic instability, but her lactate is not significantly elevated, and MAP is adequate. The question states the center has on-site ECMO with an experienced team but limited capacity.\n\nLet's analyze the options:\n\nA. Increasing PEEP to 20 cm H2O could potentially worsen V/Q mismatch and increase the risk of barotrauma, especially in a patient with severe ARDS. Permissive hypercapnia is a strategy, but the primary issue is oxygenation. Given the severity and refractory nature, this might not be sufficient.\n\nB. Initiating venovenous ECMO is a strong consideration for refractory severe ARDS. The patient has failed optimal conventional therapy, including lung-protective ventilation, paralysis, and prone positioning. ECMO provides lung rest and improves oxygenation, allowing for lung recovery. The limited capacity of the ECMO center is a factor, but the patient's condition warrants consideration.\n\nC. High-frequency oscillatory ventilation (HFOV) can be a rescue therapy for ARDS, but its effectiveness is debated, and it carries its own risks. Given the patient has already failed prone positioning, switching to HFOV might not be the most definitive next step, especially when ECMO is available.\n\nD. Inhaled nitric oxide (iNO) can improve pulmonary vasodilation and oxygenation in ARDS, but its efficacy in severe, refractory ARDS is variable. Further proning cycles might offer some benefit, but the patient has already shown only transient improvement. Considering the severity and refractory nature, waiting for these interventions to show significant improvement before considering ECMO might delay definitive therapy.\n\nE. Venoarterial (VA) ECMO is primarily indicated for cardiogenic shock or cardiac arrest. This patient is on low-dose norepinephrine with adequate MAP and a normal lactate, suggesting her hemodynamics are not the primary driver for VA ECMO. Veno-venous (VV) ECMO is the appropriate modality for isolated respiratory failure.\n\nConsidering the refractory hypoxemia despite maximal conventional management and the availability of ECMO, initiating VV ECMO is the most appropriate next step to improve oxygenation and allow for lung recovery. The limited capacity of the ECMO center is a logistical challenge, but the patient's clinical status dictates the need for this advanced therapy.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a constellation of symptoms and findings highly suggestive of **polyarteritis nodosa (PAN)**, particularly given the history of asthma (though not currently exacerbated), fever, weight loss, night sweats, joint pains, palpable purpura, mononeuritis multiplex, hypertension, elevated inflammatory markers, renal involvement (proteinuria, RBCs), and the crucial finding of microaneurysms on CT angiography. The positive hepatitis B surface antigen and high HBV DNA titer strongly point towards **hepatitis B-associated PAN**.\n\nLet's analyze the options:\n\n*   **A. High-dose corticosteroids plus cyclophosphamide without antiviral therapy:** While corticosteroids and cyclophosphamide are standard treatments for severe PAN, omitting antiviral therapy in the setting of active HBV infection is inappropriate and could lead to severe HBV flare.\n\n*   **B. Start entecavir and delay immunosuppression until HBV viral load is suppressed:** Delaying immunosuppression in a patient with active, severe PAN can lead to irreversible organ damage and worsening of the vasculitis. While antiviral therapy is crucial, it should be initiated concurrently with immunosuppression.\n\n*   **C. High-dose corticosteroids plus plasma exchange and antiviral therapy:** This option addresses the key components of managing severe HBV-associated PAN. High-dose corticosteroids are essential to control the inflammation of the vasculitis. Plasma exchange can be beneficial in removing circulating immune complexes and antibodies, especially in severe cases. Antiviral therapy (e.g., with entecavir or tenofovir) is critical to suppress HBV replication and prevent further immune complex formation and vasculitis flares. This combination is a well-established approach for severe HBV-associated PAN.\n\n*   **D. Rituximab with low-dose steroids and entecavir prophylaxis:** Rituximab is an option for PAN, but typically in cases refractory to other treatments or when cyclophosphamide is contraindicated. Low-dose steroids are unlikely to be sufficient for severe active vasculitis. Entecavir prophylaxis is not the primary treatment for active HBV infection driving the vasculitis.\n\n*   **E. Plasma exchange and entecavir only, avoiding immunosuppression:** Avoiding immunosuppression entirely is not appropriate for active, severe PAN, as it will not adequately control the underlying inflammatory process driving the vasculitis.\n\nTherefore, the most appropriate initial treatment strategy for severe HBV-associated PAN is a combination of high-dose corticosteroids, plasma exchange, and antiviral therapy.\n\nThe answer is (C)"}]